ACTRN12615000247572已完成未知
Examining the effects of a brief individually-tailored web-based parenting program (Partners in Parenting) for parents of 12- to 15-year-olds, compared to a waitlist control condition, on parental risk and protective factors for adolescent depression and anxiety disorders.
Dr Marie Yap0 个研究点目标入组 680 人开始时间: 2015年3月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 680
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Educational / counselling / training
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 12 Years 至 o limit(—)
- 性别
- All
入选标准
- •Parent Participants:
- •Parents or guardians of at least one child aged 12 to 15 years (inclusive), who reside in Australia, are fluent in English, have regular access to the internet and an email account.
- •Adolescent Participants:
- •Adolescent children of participating parents/guardians, aged 12 to 15 years (inclusive) on entry to the trial, who reside in Australia, are fluent in English, and have regular access to the internet.
- •Only one parent and one adolescent per family can participate in the trial.
排除标准
- •1. Parents who reside outside of Australia.
- •2. Parents who are not proficient in English.
- •Adolescents:
- •1. Adolescents who reside outside of Australia.
- •2. Adolescents who are not proficient in English.
- •3. Adolescents who do not have parental consent to participate in the study; or who do not provide verbal assent to participate. Note: parents can still participate if their child does not participate.
- •Parents and adolescents will not be excluded if the adolescent scores in the clinically elevated range (as determined by published clinical cut-off scores) on either the SMFQ or SCAS (either parent- or child-report form) at baseline. However, by assessing baseline symptoms, we will be able to conduct post-hoc analyses in which we exclude adolescents who scored above the clinical cut-off scores at baseline.
- •The cut-off scores used are as follows:
- •SMFQ (parent- or child-report versions): 8 or more
- •SCAS (Child-report):
- •For male children: Scores of 48 or more.
- •For female children: Scores of 51 or more.
- •SCAS (Parent-report):
- •For male children: Scores of 24 or more.
- •For female children: Scores of 26 or more.
研究者
相似试验
进行中(未招募)
1 期
eostigmine for patients with weak or absent esophageal peristalsisPatients with complaints of dysphagia and poor esophageal motilityEUCTR2019-002187-26-BEKU Leuven - TARGID20
已完成
不适用
Partners in Parenting: Evaluating an online personalised parenting programAdolescent depressionACTRN12615000328572Dr Marie Yap676
已完成
不适用
Parenting Resilient Kids: Evaluating a Personalised Online Parenting ProgramParental risk and protective factors for the development of childhood depression and anxiety disordersChild anxietyChild depressionMental Health - AnxietyMental Health - DepressionPublic Health - Health promotion/educationACTRN12616000621415Dr Marie Yap697
进行中(未招募)
1 期
A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to healthy adult participantsPlaque PsoriasisCTIS2023-509030-19-00Janssen Cilag International36
进行中(未招募)
1 期
Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosuPyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising.MedDRA version: 20.0Level: PTClassification code 10037635Term: Pyoderma gangrenosumSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-000762-65-DETechnische Universität München, School of Medicine, represented by Dean7
